Ramipril modified release - Panacea Biotec

Drug Profile

Ramipril modified release - Panacea Biotec

Alternative Names: Ramipril extended release - Panacea Biotec; Ramipril MR - Panacea Biotec; Ramy 24; Ramy24

Latest Information Update: 22 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Panacea Biotec
  • Class Antihypertensives; Heart failure therapies; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 23 Aug 2011 Panacea Biotec completes a phase III trial in Hypertension in India (CTRI/2009/091/000591)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top